Layne Beal

Layne Beal is a seasoned professional in the biotechnology and business operations sectors, currently serving in Strategic Planning & Business Operations at Dyve Biosciences since January 2021. Dyve Biosciences is a clinical-stage biotech company focused on innovative transdermal delivery methods, with its lead asset undergoing a Phase 2 clinical study for acute gout treatment. Prior to this role, Layne Beal held the position of CEO at Viridian Pharmaceuticals LLC and was VP of Corporate Development at Dyve Biosciences for a brief period. Layne Beal's extensive experience includes 14 years at PwC as Director of Risk Assurance, where expertise was demonstrated in risk advisory, audits, and IPO readiness across multiple industries. Earlier experience includes an IT Project Manager role at Qwest, where significant projects were led to enhance secure connectivity. Layne Beal holds an MBA from the University of Denver - Daniels College of Business and a BSBA in CIS from Colorado State University.